The global osteoarthritis therapeutics market is estimated to grow at a CAGR of 8.2% during the forecast period. Pipeline products are expected to offer an opportunity for the growth of the market. For instance, in April 2019, Pfizer Inc. and Eli Lilly and Co. declared a Phase III study outcomes assessing tanezumab 2.5 mg and 5 mg. […]
